Antag Therapeutics has initiated a first-in-human, double-blind Phase Ia trial of the glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist, AT-7687, intended for treating obesity.

Researchers at the Pennington Biomedical Research Center conducted a first-of-its-kind study to provide insights into the ...

The escalating global prevalence of obesity and type 2 diabetes mellitus (T2DM) underscores the urgent need for innovative therapeutic approaches capable of addressing multiple metabolic pathways ...

At the end of 2023, more than one-third of new prescriptions to treat Type 2 diabetes were GLP-1s, such as Mounjaro and Ozempic, among others, according to a study published April 15 in Annals of ...

Stimulating a receptor in adipocytes enhanced energy expenditure and caused sustained weight loss in mice, offering targets ...

Increased awareness and knowledge of GLP-1/GIP receptor agonists among women, with insights into public perspectives on ...

was given the green light by the US Food and Drug Administration after the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 glucagon-like peptide-1 (GLP-1 ) receptor agonist showed its ...

ACC, Acetyl-CoA Carboxylase; PPAR, peroxisome proliferator–activated receptor; MPC, mitochondrial pyruvate carrier; THR, thyroid hormone receptor; ASK-1, apoptosis signaling kinase-1; GLP-1R ...